JD Health Likely Outpacing Rivals -- Market Talk

Dow Jones12-11

0716 GMT - JD Health's growth momentum is outpacing peers, supported by multiple partnership with global pharma majors including Eli Lilly, Morningstar analyst Kai Wang says in a note. The company posted a 29% on-year increase in 3Q revenue. Wang says JD Health is supported by its strengths in logistics and user-acquisition. Its expanding product portfolio could create a network effect, aided by its tie-ups with major pharma companies, he says. "We view JD Health favorably, given its narrow moat, and believe a pullback could present an attractive entry point," Wang adds. Morningstar maintains a fair value estimate of HK$58.00 as 3Q revenue was in line with the company forecast. Shares last traded at HK$58.30. (jason.chau@wsj.com)

(END) Dow Jones Newswires

December 11, 2025 02:16 ET (07:16 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590603455?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 15:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590603455","market":"hk","top_or_hot":-1,"title":"JD Health Likely Outpacing Rivals -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0716 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health's growth momentum is outpacing peers, supported by multiple partnership with global pharma majors including Eli Lilly, Morningstar analyst Kai Wang says in a note. The company posted a 29% on-year increase in 3Q revenue. Wang says JD Health is supported by its strengths in logistics and user-acquisition. Its expanding product portfolio could create a network effect, aided by its tie-ups with major pharma companies, he says. \"We view JD Health favorably, given its narrow moat, and believe a pullback could present an attractive entry point,\" Wang adds. Morningstar maintains a fair value estimate of HK$58.00 as 3Q revenue was in line with the company forecast. Shares last traded at HK$58.30. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 11, 2025 02:16 ET (07:16 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health Likely Outpacing Rivals -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health Likely Outpacing Rivals -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-11 15:16</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0716 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health's growth momentum is outpacing peers, supported by multiple partnership with global pharma majors including Eli Lilly, Morningstar analyst Kai Wang says in a note. The company posted a 29% on-year increase in 3Q revenue. Wang says JD Health is supported by its strengths in logistics and user-acquisition. Its expanding product portfolio could create a network effect, aided by its tie-ups with major pharma companies, he says. \"We view JD Health favorably, given its narrow moat, and believe a pullback could present an attractive entry point,\" Wang adds. Morningstar maintains a fair value estimate of HK$58.00 as 3Q revenue was in line with the company forecast. Shares last traded at HK$58.30. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 11, 2025 02:16 ET (07:16 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4558","symbol_name":"双十一","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590603455","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590603455","pubTimestamp":1765437360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0716 GMT - JD Health's growth momentum is outpacing peers, supported by multiple partnership with global pharma majors including Eli Lilly, Morningstar analyst Kai Wang says in a note. The company posted a 29% on-year increase in 3Q revenue. Wang says JD Health is supported by its strengths in logistics and user-acquisition. Its expanding product portfolio could create a network effect, aided by its tie-ups with major pharma companies, he says. \"We view JD Health favorably, given its narrow moat, and believe a pullback could present an attractive entry point,\" Wang adds. Morningstar maintains a fair value estimate of HK$58.00 as 3Q revenue was in line with the company forecast. Shares last traded at HK$58.30. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","BK4558":"双十一","BK4505":"高瓴资本持仓","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK4504":"桥水持仓","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","06618":"京东健康","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK4579":"人工智能","BK1589":"北水核心资产","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","BK4614":"Manus概念股","BK4588":"碎股","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","BK1142":"互联网与直销零售","LU0051755006.USD":"摩根大通中国A (dist)","LU1688375341.USD":"贝莱德中国灵活股票基金","IE0008368742.USD":"首域中国增长基金I Acc","BK4551":"寇图资本持仓","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK4509":"腾讯概念","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK4220":"综合零售","BK4524":"宅经济概念","BK1615":"港股-互联网","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK1571":"互联网医疗","BK4531":"中概回港概念","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK1515":"抗疫概念","BK4526":"热门中概股","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","BK1591":"就地过年概念","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","BK4503":"景林资产持仓","BK1247":"药品零售","BK4122":"互联网与直销零售","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","BK1583":"高瓴概念"},"translate_title":"京东健康可能超越竞争对手——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"06618":1.96},"content_text":"0716 GMT - JD Health's growth momentum is outpacing peers, supported by multiple partnership with global pharma majors including Eli Lilly, Morningstar analyst Kai Wang says in a note. The company posted a 29% on-year increase in 3Q revenue. Wang says JD Health is supported by its strengths in logistics and user-acquisition. Its expanding product portfolio could create a network effect, aided by its tie-ups with major pharma companies, he says. \"We view JD Health favorably, given its narrow moat, and believe a pullback could present an attractive entry point,\" Wang adds. Morningstar maintains a fair value estimate of HK$58.00 as 3Q revenue was in line with the company forecast. Shares last traded at HK$58.30. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 02:16 ET (07:16 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590603455","isCrawlerRequest":true}